Research programme: neuropathic pain therapeutics - EicOsisAlternative Names: EC 5026
Latest Information Update: 28 Jul 2016
At a glance
- Originator EicOsis
- Class Small molecules
- Mechanism of Action Epoxide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic neuropathies; Neuropathic pain
Most Recent Events
- 28 Jul 2016 Preclinical trials in Neuropathic pain in USA (PO)
- 28 Jul 2016 Preclinical trials in Diabetic neuropathies in USA (PO)